Acadia Pharmaceuticals (ACAD) closed at $21.23 on November 6, 2026, unchanged from the previous close, on volume of 1,478,302 shares (30-day average 2,012,336).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 15, 2026 | Put Spread | 16-Oct-2626 : 27 P | 5,800 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Canaccord Genuity Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)
TipRanks (Fri, 6-Nov 9:56 AM ET)
TipRanks (Thu, 5-Nov 6:00 PM ET)
Acadia raises 2026 DAYBUE guidance after Q3 sales jump to $140 million
Market Chameleon (Thu, 5-Nov 6:15 AM ET)
TipRanks (Thu, 5-Nov 9:02 AM ET)
TipRanks (Thu, 5-Nov 8:50 AM ET)
BMO Capital Reaffirms Their Buy Rating on ACADIA Pharmaceuticals (ACAD)
TipRanks (Thu, 5-Nov 8:28 AM ET)
TipRanks (Thu, 5-Nov 8:20 AM ET)
TipRanks (Thu, 5-Nov 8:10 AM ET)
Acadia Pharma GAAP EPS of $0.31 beats by $0.12, revenue of $342M beats by $9.45M
Seeking Alpha News (Wed, 4-Nov 4:14 PM ET)
Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
Business Wire (Wed, 4-Nov 4:05 PM ET)
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
Acadia Pharmaceuticals trades on the NASDAQ stock market under the symbol ACAD.
As of November 6, 2026, ACAD stock price declined to $21.23 with 1,478,302 million shares trading.
ACAD has a beta of 0.61, meaning it tends to be less sensitive to market movements. ACAD has a correlation of 0.03 to the broad based SPY ETF.
ACAD has a market cap of $3.63 billion. This is considered a Mid Cap stock.
Last quarter Acadia Pharmaceuticals reported $342 million in Revenue and $.31 earnings per share. This beat revenue expectation by $9 million and exceeded earnings estimates by $.13.
In the last 3 years, ACAD traded as high as $32.59 and as low as $13.40.
The top ETF exchange traded funds that ACAD belongs to (by Net Assets): IJR, VTI, IWM, VB, XBI.
ACAD has underperformed the market in the last year with a return of -1.9%, while the SPY ETF gained +10.8%. In the last 3 month period, ACAD fell short of the market, returning -25.4%, while SPY returned -4.1%. However, in the most recent 2 weeks ACAD has outperformed the stock market by returning +7.6%, while SPY returned -3.2%.
ACAD support price is $20.75 and resistance is $21.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACAD shares will trade within this expected range on the day.
